What is Agile Therapeutics?
Based in Princeton, New Jersey, Agile Therapeutics operates as a specialized women's healthcare company. The firm is primarily focused on addressing unmet medical needs by developing innovative contraceptive options that offer patients greater flexibility and freedom from daily medication requirements. By leveraging advanced delivery technologies, the company aims to improve patient compliance and overall health outcomes within the reproductive health market. Their market position is defined by a commitment to clinical excellence and the development of therapeutic products that cater to the modern lifestyle of women.
How much funding has Agile Therapeutics raised?
Agile Therapeutics has raised a total of $192.4M across 10 funding rounds:
Series E
$17.6M
Multiple Rounds
$49M
Series C
$40M
Debt
$3M
Stock Offering
$55M
Share Placement
$20M
Share Placement
$7.8M
Series E (2007): $17.6M with participation from TL Ventures, The Hillman Company, Novitas Capital, and ProQuest Investments
Series A (2010): $2M, investors not publicly disclosed
Series A (2010): $1M, investors not publicly disclosed
Debt (2010): $990K, investors not publicly disclosed
Series B (2010): $45M backed by Novitas Capital, Care Capital, Investor Growth Capital Limited, and Kaiser Permanente Ventures
Series C (2012): $40M with participation from Investor Growth Capital Limited, Kaiser Permanente Ventures, Novitas Capital, Aisling Capital, and Care Capital
Debt (2014): $3M, investors not publicly disclosed
Stock Issuance/Offering (2014): $55M, investors not publicly disclosed
Share Placement (2015): $20M featuring RA Capital Management, Aisling Capital, and CAM Capital
Share Placement (2019): $7.8M backed by Perceptive Advisors
Key Investors in Agile Therapeutics
Perceptive Advisors
A New York-based investment firm managing approximately $7 billion in assets, specializing in funding innovative healthcare and life sciences technologies.
RA Capital Management
A multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, utilizing an internal think tank to guide strategy.
Aisling Capital
A leading investment firm with over $1.8 billion in assets, dedicated to investing in transformative healthcare solutions and biopharmaceutical development.
What's next for Agile Therapeutics?
Looking ahead, the strategic deployment of the $7.8M is expected to bolster the company's clinical development programs and commercial infrastructure. As Agile Therapeutics moves deeper into its lifecycle, the focus will likely shift toward expanding market penetration and optimizing the delivery of its contraceptive portfolio. The continued support from high-profile life sciences investors suggests a long-term commitment to scaling the company's reach within the competitive biopharmaceutical landscape. Future growth will depend on the successful execution of regulatory milestones and the ability to maintain a competitive edge in the evolving women's health sector.
See full Agile Therapeutics company page
